Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masako Shimada has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fucoidan Treatment Improves Diabetic Hyperglycemia and Dyslipidemia in Rodents: A Systematic Review and Meta-Analysis

    by Kana Watanuki, Rin Akiyama, Shiita Watanabe, Eri Adachi, Masako Shimada

    Background/Objectives: Fucoidan is a sulfated long-chain polysaccharide found mainly in sea cucumbers and brown algae. Studies suggest that fucoidan may play a role in treating various diseases, including metabolic syndrome and diabetes mellitus. The purpose of the current study was to investigate the effects of fucoidan isolated from brown algae on diabetic hyperglycemia and dyslipidemia. Methods: Two databases, PubMed and Embase, were searched to identify peer-reviewed articles written in English and published up to 30 June 2025. Studies reporting blood glucose and serum/plasma lipid levels of diabetic rodents treated with fucoidan or vehicle were included in the meta-analysis. Results: Forty-seven studies reported blood glucose levels. The pooled effect size for blood glucose levels was −2.26 (95% CI: −2.78 to −1.75), with substantial heterogeneity. Subsequent analyses showed that diabetic dyslipidemia was markedly improved in the fucoidan-treated group compared with the control. Conclusions: Fucoidan treatment could improve hyperglycemia and dyslipidemia in diabetic rodents.

  • Open Access

    Arctium lappa Lam. and Its Related Lignans Improve Hyperglycemia and Dyslipidemia in Diabetic Rodent Models: A Systematic Review and Meta-Analysis

    by Shihori Watanabe, Shizuko Yamabe, Masako Shimada

    Research on nutraceuticals has focused on reducing the onset, progression, and significant consequences of diabetes mellitus. Arctium lappa Lam. is a great source of plant fibers and polyphenols that have anti-disease benefits, including those for diabetes mellitus. This study sought to determine the impact of Arctium lappa Lam. extracts and its associated lignans on diabetic hyperglycemia and dyslipidemia by conducting meta-analyses of the available research using diabetic rodents. English-language peer-reviewed articles were searched by PubMed and Embase up until 10 August 2022. Included were studies comparing the blood glucose and/or lipid levels of diabetic rodents given either extracts of Arctium lappa Lam. and its related lignans or vehicles. Blood glucose levels were reported in 16 studies involving 168 diabetic mice or rats treated with Arctium lappa Lam. and 168 diabetic controls. The pooled effect size was −1.42 [95% CI: −1.84 to −1.00] with significant heterogeneity. Type of diabetic model was found to be the prominent covariate that explained, at least partially, the heterogeneity. Moreover, diabetic rodents treated with Arctium lappa Lam. showed a notable improvement in their hypertriglyceridemia and hypercholesterolemia.


  • Open Access

    Moringa oleifera Lam. in Diabetes Mellitus: A Systematic Review and Meta-Analysis

    by Shihori Watanabe, Hiyori Okoshi, Shizuko Yamabe, Masako Shimada

    Plant-derived phytochemicals have been interested in as nutraceuticals for preventing the onset and progress of diabetes mellitus and its serious complications in recent years. Moringa oleifera Lam. is used in vegetables and in herbal medicine for its health-promoting properties against various diseases including diabetes mellitus. This study aimed to examine an effect of Moringa oleifera on diabetic hyperglycemia and dyslipidemia by meta-analyzing the current evidence of diabetic rodent models. Peer-reviewed studies written in English from two databases, PubMed and Embase, were searched to 30 April 2021. Studies reporting blood glucose or lipid levels in diabetic rodents with and without receiving extracts of Moringa oleifera were included. Forty-four studies enrolling 349 diabetic rodents treated with extracts of Moringa oleifera and 350 diabetic controls reported blood glucose levels. The pooled effect size was −3.92 (95% CI: −4.65 to −3.19) with a substantial heterogeneity. This effect was likely to be, at least in part, modified by the type of diabetic models. Moreover, diabetic hypertriglyceridemia and hypercholesterolemia were also significantly improved in diabetic rodent models treated with Moringa oleifera.


  • Open Access

    A Beneficial Role of Rooibos in Diabetes Mellitus: A Systematic Review and Meta-Analysis

    by Moe Sasaki, Nami Nishida, Masako Shimada

    In a rapid increase in cases of diabetes mellitus worldwide, there has been interested in the use of plant-derived polyphenols as nutraceuticals to prevent the onset and progression of diabetes mellitus and its associated complications. Aspalathus linearis, commonly known as rooibos, is a rich source of uncommon glycosylated plant polyphenols with various critical health-promoting properties, including the prevention and treatment of diabetes mellitus (DM). This study aimed to examine these effects by meta-analyzing the current evidence in diabetic rodent models. Peer-reviewed studies written in English from two databases, PubMed and Embase, were searched up to 28 February 2018. Studies reporting blood glucose levels in diabetic rodents with and without receiving rooibos extracts or their major phenolic compounds are included. Twelve studies enrolling 88 diabetic rodents treated with rooibos extracts or their polyphenols and 85 diabetic control males reported blood glucose levels. The pooled effect size was −0.89 (95% CI: −1.44 to −0.35) with a substantial heterogeneity (I2 = 67.0%). This effect was likely to be modified by type of rooibos extracts and their polyphenols and treatment period. Blood glucose levels were significantly lower in diabetic rodent models treated with the phenolic compound rich in rooibos extracts, PPAG.


  • Open Access

    Crucial Role of Elovl6 in Chondrocyte Growth and Differentiation during Growth Plate Development in Mice

    by Manami Kikuchi, Masako Shimada, Takashi Matsuzaka, Kiyoaki Ishii, Yoshimi Nakagawa, Misa Takayanagi, Nobuhiro Yamada, Hitoshi Shimano

    ELOVL family member 6, elongation of very long chain fatty acids (Elovl6) is a microsomal enzyme, which regulates the elongation of C12-16 saturated and monounsaturated fatty acids. Elovl6 has been shown to be associated with various pathophysiologies including insulin resistance, atherosclerosis, and non-alcoholic steatohepatitis. To investigate a potential role of Elovl6 during bone development, we here examined a skeletal phenotype of Elovl6 knockout (Elovl6-/-) mice. The Elovl6-/- skeleton was smaller than that of controls, but exhibited no obvious patterning defects. Histological analysis revealed a reduced length of proliferating and an elongated length of hypertrophic chondrocyte layer, and decreased trabecular bone in Elovl6-/- mice compared with controls. These results were presumably due to a modest decrease in chondrocyte proliferation and accelerated differentiation of cells of the chondrocyte lineage. Consistent with the increased length of the hypertrophic chondrocyte layer in Elovl6-/- mice, Collagen10α1 was identified as one of the most affected genes by ablation of Elovl6 in chondrocytes. Furthermore, this elevated expression of Collagen10α1 of Elovl6-null chondrocytes was likely associated with increased levels of Foxa2/a3 and Mef2c mRNA expression. Relative increases in protein levels of nuclear Foxa2 and cytoplasmic histone deacethylase 4/5/7 were also observed in Elovl6 knockdown cells of the chondrocyte lineage. Collectively, our data suggest that Elovl6 plays a critical role for proper development of embryonic growth plate.


  • Open Access

    TFE3 Controls Lipid Metabolism in Adipose Tissue of Male Mice by Suppressing Lipolysis and Thermogenesis

    by Yuri Fujimoto, Yoshimi Nakagawa, Aoi Satoh, Kanako Okuda, Akiko Shingyouchi, Ayano Naka, Takashi Matsuzaka, Hitoshi Iwasaki, Kazuto Kobayashi, Naoya Yahagi, et al.

    Transcription factor E3 (TFE3) is a transcription factor that binds to E-box motifs and promotes energy metabolism-related genes. We previously reported that TFE3 directly binds to the insulin receptor substrate-2 promoter in the liver, resulting in increased insulin response. However, the role of TFE3 in other tissues remains unclear. In this study, we generated adipose-specific TFE3 transgenic (aP2-TFE3 Tg) mice. These mice had a higher weight of white adipose tissue (WAT) and brown adipose tissue than wild-type (WT) mice under fasting conditions. Lipase activity in the WAT in these mice was lower than that in the WT mice. The mRNA level of adipose triglyceride lipase (ATGL), the rate-limiting enzyme for adipocyte lipolysis, was significantly decreased in aP2-TFE3 Tg mice. The expression of Foxo1, which directly activates ATGL expression, was also suppressed in transgenic mice. Promoter analysis confirmed that TFE3 suppressed promoter activities of the ATGL gene. In contrast, G0S2 and Perilipin1, which attenuate ATGL activity, were higher in transgenic mice than in WT mice. These results indicated that the decrease in lipase activity in adipose tissues was due to a decrease in ATGL expression and suppression of ATGL activity. We also showed that thermogenesis was suppressed in aP2-TFE3 Tg mice. The decrease in lipolysis in WAT of aP2-TFE3 Tg mice inhibited the supply of fatty acids to brown adipose tissue, resulting in the inhibition of the expression of thermogenesis-related genes such as UCP1. Our data provide new evidence that TFE3 regulates lipid metabolism by controlling the gene expression related to lipolysis and thermogenesis in adipose tissue.


  • TFE3 inhibits myoblast differentiation in C2C12 cells via down-regulating gene expression of myogenin

    by Ayano Naka, Kaoruko Tada Iida, Yoshimi Nakagawa, Hitoshi Iwasaki, Yoshinori Takeuchi, Aoi Satoh, Takashi Matsuzaka, Kiyo-Aki Ishii, Kazuto Kobayashi, Shigeru Yatoh, et al.


  • Overview of Calpain-Mediated Regulation of Bone and Fat Mass in Osteoblasts

    by Masako Shimada

    The receptor for parathyroid hormone (PTH) and PTH-related peptide (PTH1R) belongs to the class II G protein-coupled receptor superfamily. The calpain small subunit encoded by the gene Capns1 is the second protein and the first enzyme identified by a yeast two-hybrid screen using the intracellular C-terminal tail of the rat PTH1R. The calpain regulatory small subunit forms a heterodimer with the calpain large catalytic subunit and modulates various cellular functions as a cysteine protease. To investigate a physiological role of the calpain small subunit in cells of the osteoblast lineage, we generated osteoblast-specific Capns1 knockout mouse models and characterized their bone phenotype. Molecular mechanisms by which calpain modulates cell proliferation of the osteoblast lineage were further examined in vitro. Moreover, we utilized the mutant mice as a disease model of osteoporosis accompanied with impaired bone resorptive function and suggested a possible clinical translation of our basic research finding.


  • Open Access

    Elovl6 promotes nonalcoholic steatohepatitis

    by Takashi Matsuzaka, Ayaka Atsumi, Rie Matsumori, Tang Nie, Haruna Shinozaki, Noriko Suzuki-Kemuriyama, Motoko Kuba, Yoshimi Nakagawa, Kiyoaki Ishii, Masako Shimada, et al.

    Nonalcoholic steatohepatitis (NASH) is associated with obesity and type 2 diabetes, and an increased risk for liver cirrhosis and cancer. ELOVL family member 6, elongation of very long chain fatty acids (Elovl6), is a microsomal enzyme that regulates the elongation of C12-16 saturated and monounsaturated fatty acids (FAs). We have shown previously that Elovl6 is a major target for sterol regulatory element binding proteins in the liver and that it plays a critical role in the development of obesity-induced insulin resistance by modifying FA composition. To further investigate the role of Elovl6 in the development of NASH and its underlying mechanism, we used three independent mouse models with loss or gain of function of Elovl6, and human liver samples isolated from patients with NASH. Our results demonstrate that (1) Elovl6 is a critical modulator for atherogenic high-fat diet–induced inflammation, oxidative stress, and fibrosis in the liver; (2) Elovl6 expression is positively correlated with severity of hepatosteatosis and liver injury in NASH patients; and (3) deletion of Elovl6 reduces palmitate-induced activation of the NLR family pyrin domain-containing 3 inflammasome; this could be at least one of the underlying mechanisms by which Elovl6 modulates the progress of NASH. Conclusion: Hepatic long-chain fatty acid composition is a novel determinant in NASH development, and Elovl6 could be a potential therapeutic target for the prevention and treatment of NASH. (HEPATOLOGY 2012;56:2199–2208)